期刊文献+

7例原发性腹膜癌的诊治 被引量:1

下载PDF
导出
摘要 目的探讨原发腹膜癌的诊断及治疗。方法对7例原发腹膜癌的临床资料进行分析。结果本组年龄48~69岁,从症状出现到就诊时间3周~4个月,以腹胀、腹部增大为主诉,均有腹腔积液5,例有盆腔包块,手术后病理诊断7例均为浆液性乳头状腺癌。均行肿瘤细胞减灭手术及化疗(顺铂部分腹腔灌注),本组患者治疗后CA125 3例接近正常,4例达到正常,疗效评价完全缓解。结论原发腹膜癌起病隐匿,发展迅速,腹胀、腹水老年女性患者有原发腹膜癌的可能,肿瘤细胞减灭术和以顺铂为主的化疗是目前治疗原发腹膜癌的有效方法,采用顺铂部分腹腔灌注化疗可降低药物毒性。
出处 《宁夏医科大学学报》 2010年第9期1009-1010,共2页 Journal of Ningxia Medical University
  • 相关文献

参考文献5

  • 1曹泽毅.中华妇产科学[M]:下册.2版.北京:人民卫生出版社,2004:2178-2179.
  • 2Bloss JD,Liao SY,Buller RE,et al.Extraovarian perítoneal serous papillary carcinoma:a case-control retrospective comparison to papillary adenocarcinoma of the ovary[J].Cynecol Oncol,1993,50:347-351.
  • 3崔恒.原发腹膜癌的诊断与治疗[J].中国妇产科临床杂志,2005,6(5):323-325. 被引量:4
  • 4Yen MS,Juangcm Laicr.Intraperitoncal Cisplatin based chemotherapy Vs intravenous cisplatin-_based chemotherapy for stage Ⅲ optimally cytoreduced epithecial ovariancancer[J].Int J Gynaecol Bestet,2001,72(1):55.
  • 5王志华,贾忠,张令云.原发性腹膜癌诊断和治疗[J].医学研究杂志,2008,37(4):102-103. 被引量:3

二级参考文献13

  • 1高雨农,刘静贤,王文,李蔚范,汤望舒.卵巢外腹膜浆液性乳头状癌与卵巢浆液性乳头状癌比较分析[J].中华肿瘤杂志,2005,27(3):171-173. 被引量:8
  • 2张超,崔恒,赵彦,梁旭东,王朝华,李小平,沈丹华,王世军,魏丽惠.原发性腹膜恶性肿瘤的治疗及预后分析[J].中华妇产科杂志,2005,40(7):464-468. 被引量:13
  • 3[1]Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol,1993, 50: 347-351.
  • 4[2]Gompel C, Silverberg SG. The female peritoneum. In Gompel C, Silverberg SG (eds): Pathology in Gynecology and Obstetrics. Philadelphia: JB Lippincott, 1994.414.
  • 5[3]Weir MM, Bell DA, Young RH. Grade 1 peritoneal serous carcinoma: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors. Am J Surg Pathol, 1998,22: 849.
  • 6[4]Fromm GL, Gershenson DM, Silva EG, et al. Papillary serous carcinoma of the peritoneum.Obstet Gynecol,1990, 75:89-95.
  • 7[5]Eltabbakh GH, Piver S, Natarajan N, et al. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol, 1998,91:254-259.
  • 8[6]Bloss JD, Brady MF, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma:a phase Ⅱ trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecologic Oncology, 2003, 89:148-154.
  • 9[7]Eltabbakh GH, Werness BA, Piver MS, et al. Prognostic factors in extra-ovarian primary peritoneal carcinoma. Gynecol Oncol, 1998, 71: 230-239.
  • 10[8]Piver MS, Eltabbakh GH, Hempling RE, et al. Two sequential studies for primary peritoneal carcimoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophoaphamide or paclitaxel-cisplatin. Gynecol Oncol,1997,67:141-146.

共引文献5

同被引文献12

  • 1Chao KC,Chen YJ, Juang CM, et al. Prognosis foradvancedstage primary peritoneal serous papillary carcinoma andserous ovarian cancer in Taiwan [ J ]. Taiwan J Obstet Gynecol,2013,52(1): 81-84.
  • 2Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal se-rous papillary carcinoma : a case-control retrospective comparisonto papillary adenocarcinoma of the ovary [ J ]. Gynecol Oncol,1993,50(3) : 347-351.
  • 3Moccia F, Cimmino M, Ciancia G, et al. A case of extraovarianprimary peritoneal carcinoma in an ophorectomized-hysterectomized patient: a diagnostic dilemma [ J ]. G Chir,2013, 34(3): 82-85.
  • 4Liu Q, Lin JX, Shi QL, et al. Primary peritoneal serous papillarycarcinoma: a clinical and pathological study [ J]. Pathol OncolRes, 2011, 17(3) : 713-719.
  • 5Levy T, Weiser R,Boaz M, et al. The significance of the patternof serum CA125 level ascent to above the normal rangeinepithelial ovarian, primary peritoneal and tubal carcinomapatients[ J]. Gynecol Oncol,2013,129( 1) : 165-168.
  • 6Chi DS, Zivanovic 0,Palayekar MJ, et al. A contemporary anal-ysis of the ability of preoperative serum CA125 to predict primarycytoreductive outcome in patients with advanced ovarian,tube andperitoneal carcinoma[ J]. Gynecol Oncol, 2009, 112(4) : 6-10.
  • 7Secord AA, Blessing JA, Armstrong DK, et al. Phase II trial ofcetuximab and carboplatin in relapsed platinum sensitive ovariancancer and evaluation of epidermal growth factor receptor expres-sion :a Gynecologic Oncology Group study[ J]. Gynecol Oncol,2008, 108(3):493-499.
  • 8Burger RA, Sill MW, Monk BJ,et al. Phase H trial of bevaci-zumab in persistent or recurrent epithelial ovarian cancer or pri-mary peritoneal cancer : a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2007,25(33) :5165-5171.
  • 9Zhang MM, Chan JK, Husain A, et al. Safety and efficacy of le-nalidomide ( revlimid ) in recurrent ovarian and primaryperitoneal carcinoma [ J ] . Gynecol Oncol,2007,105 (1) : 194-198.
  • 10Lenzi R, Edwards R, June C, et al. Phase II study of intraper-itoneal recombinant interleukin-12( rhIL-12) in patients with per-itoneal carcinomatosis ( residual disease < 1 cm) associated withovarian cancer or primary peritoneal carcinoma [ J/OL ] . J TranslMed, 2007,5 [ 2015-04-22]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248163.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部